M. Inoue

发表

Aminopeptidase P3, a new member of the TNF–TNFR2 signaling complex, induces phosphorylation of JNK1 and JNK2

Y. Yoshioka, Y. Tsutsumi, H. Kamada, 2015, Journal of Cell Science.

αvβ3-Integrin-targeting lanthanide complex: synthesis and evaluation as a tumor-homing luminescent probe.

S. Nishimoto, Takeo Ito, M. Inoue, 2011, Bioorganic & medicinal chemistry letters.

Novel protein engineering strategy for creating highly receptor-selective mutant TNFs.

Y. Yoshioka, Y. Tsutsumi, S. Nakagawa, 2009, Biochemical and biophysical research communications.

Ephrin receptor A10 is a promising drug target potentially useful for breast cancers including triple negative breast cancers.

Y. Yoshioka, Y. Tsutsumi, H. Kamada, 2014, Journal of controlled release : official journal of the Controlled Release Society.

Generation and characterization of a bispecific diabody targeting both EPH receptor A10 and CD3.

Y. Yoshioka, Y. Tsutsumi, H. Kamada, 2015, Biochemical and biophysical research communications.

Fine tuning of receptor-selectivity for tumor necrosis factor-α using a phage display system with one-step competitive panning.

Y. Yoshioka, Y. Tsutsumi, S. Nakagawa, 2011, Biomaterials.

A trimeric structural fusion of an antagonistic tumor necrosis factor-α mutant enhances molecular stability and enables facile modification

Y. Tsutsumi, Takashi Tadokoro, Tsuyoshi Inoue, 2017, The Journal of Biological Chemistry.

Structural optimization of a TNFR1-selective antagonistic TNFα mutant to create new-modality TNF-regulating biologics

Y. Tsutsumi, H. Kamada, S. Tsunoda, 2020, The Journal of Biological Chemistry.

Therapeutic effect of PEGylated TNFR1-selective antagonistic mutant TNF in experimental autoimmune encephalomyelitis mice.

Y. Yoshioka, Y. Tsutsumi, S. Nakagawa, 2011, Journal of controlled release : official journal of the Controlled Release Society.

Eph receptor A10 has a potential as a target for a prostate cancer therapy.

Y. Yoshioka, Y. Tsutsumi, H. Kamada, 2014, Biochemical and biophysical research communications.

Creation of an improved mutant TNF with TNFR1-selectivity and antagonistic activity by phage display technology.

Y. Yoshioka, Y. Tsutsumi, S. Nakagawa, 2010, Die Pharmazie.

Annexin A4 is a possible biomarker for cisplatin susceptibility of malignant mesothelioma cells.

Y. Yoshioka, Y. Tsutsumi, H. Kamada, 2012, Biochemical and biophysical research communications.

Creation of mouse TNFR2-selective agonistic TNF mutants using a phage display technique

Y. Tsutsumi, H. Kamada, K. Nagano, 2016, Biochemistry and biophysics reports.

Epidermal growth factor receptor localized to exosome membranes as a possible biomarker for lung cancer diagnosis.

Y. Yoshioka, Y. Tsutsumi, H. Kamada, 2013, Die Pharmazie.

A Novel Bispecific Antibody against Human CD3 and Ephrin Receptor A10 for Breast Cancer Therapy

Y. Yoshioka, Y. Tsutsumi, H. Kamada, 2015, PloS one.

Ephrin type-A receptor 2 on tumor-derived exosomes enhances angiogenesis through the activation of MAPK signaling.

Y. Yoshioka, Y. Tsutsumi, H. Kamada, 2019, Die Pharmazie.

Expression of Eph receptor A10 is correlated with lymph node metastasis and stage progression in breast cancer patients

Y. Yoshioka, Y. Tsutsumi, H. Kamada, 2013, Cancer medicine.

Characterization of a TNFR2-Selective Agonistic TNF-α Mutant and Its Derivatives as an Optimal Regulatory T Cell Expander

Y. Tsutsumi, H. Kamada, S. Tsunoda, 2021, The Journal of Immunology.

Generation of a sensitive TNFR2-specific murine assays system.

Y. Tsutsumi, H. Kamada, K. Nagano, 2016, Pharmazie.

Bivalent structure of a TNFR2-selective and agonistic TNF-α mutein Fc-fusion protein enhances the expansion activity of regulatory T cells

H. Kamada, S. Tsunoda, Y. Abe, 2023, Scientific reports.

Ephrin receptor A10 is a promising drug target potentially useful for breast cancers including triple negative breast cancers.

Y. Yoshioka, Y. Tsutsumi, H. Kamada, 2014, Journal of controlled release : official journal of the Controlled Release Society.